Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Might Face Funding Penalty For Missing User Fee Goals

Apr 04 2017

• By Derrick Gingery

Capitol House

Related Content

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself

Apr 11 2016

Trump's Budget Outline Threatens User Fee Agreements

Mar 17 2017

User Fees: Should US FDA Incur Penalties For Missed Deadlines?

Mar 27 2017

The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity

Mar 23 2017

FDA User Fee Hearing Hijacked By US Health Care Reform Arguments

Mar 22 2017

US FDA Faces Hiring Slowdown, Funding Cuts In Trump's FY 17 Plan

Mar 29 2017

Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance

Apr 02 2015

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

Additional Topics

United States FDA Legislation Regulation Drug Review BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window